Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre randomised, double blind, active controlled, parallel group comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patients.

Next Previous
Trial Profile

A multicentre randomised, double blind, active controlled, parallel group comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patients.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrochlorothiazide/nebivolol (Primary) ; Irbesartan/hydrochlorothiazide
  • Indications Isolated systolic hypertension
  • Focus Therapeutic Use
  • Acronyms NEHIS
  • Sponsors Menarini

    • Most Recent Events

    • 22 Oct 2016 Results published in the Advances in Therapy
    • 15 Jun 2015 Primary efficacy endpoint 'change in systolic blood pressure (24-hour mean SBP)' has been met as per the abstract presented at 25th European Meeting on Hypertension and Cardiovascular Protection.
    • 15 Jun 2015 Results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top